H.R. 417 (109th): Medical Innovation Prize Act of 2005

Introduced:
Jan 26, 2005 (109th Congress, 2005–2006)
Status:
Died (Referred to Committee)
Sponsor
Bernard “Bernie” Sanders
Representative for Vermont At Large
Party
Independent
Text
Read Text »
Last Updated
Jan 26, 2005
Length
21 pages
Related Bills
S. 2210 (110th) was a re-introduction of this bill in a later Congress.

Referred to Committee
Last Action: Oct 19, 2007

 
Status

This bill was introduced on January 26, 2005, in a previous session of Congress, but was not enacted.

Progress
Introduced Jan 26, 2005
Referred to Committee Jan 26, 2005
 
Full Title

To provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes.

Summary

No summaries available.

Cosponsors
none
Committees

House Energy and Commerce

Health

House Judiciary

Courts, Intellectual Property, and the Internet

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


1/26/2005--Introduced.
Medical Innovation Prize Act of 2005 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use a drug, a biological product, or a manufacturing process for a drug or biological product in interstate commerce, notwithstanding current Federal laws providing otherwise, including laws governing patent rights or exclusive marketing periods.
Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process for a drug or biological product.
Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent.
Directs the Board to consider:
(1) the number of patients who benefited from the drug, including non-U.S. patients;
(2) the incremental therapeutic benefit of the drug to treat the same disease or condition;
(3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and
(4) the improved efficiency of manufacturing processes for drugs or biological processes.
Allows the Board to award prize payments for no more than ten years.
Allocates certain minimum payments from the Fund for priority research and development.
Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and addressing society's global medical needs.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 417 (109th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus